Genelabs Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Genelabs Technologies's estimated annual revenue is currently $4.8M per year.
- Genelabs Technologies's estimated revenue per employee is $155,000
Employee Data
- Genelabs Technologies has 31 Employees.
- Genelabs Technologies grew their employee count by 0% last year.
Genelabs Technologies's People
| Name | Title | Email/Phone |
|---|
Genelabs Technologies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $10.1M | 65 | 5% | N/A | N/A |
#10 | $16.1M | 104 | 9% | N/A | N/A |
What Is Genelabs Technologies?
Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.
keywords:N/A
N/A
Total Funding
31
Number of Employees
$4.8M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.7M | 31 | 7% | N/A |
#2 | $3.6M | 31 | -14% | N/A |
#3 | $4.5M | 31 | -14% | N/A |
#4 | $6.7M | 31 | -11% | N/A |
#5 | $6.7M | 31 | 3% | N/A |